Response To: ‘Mandatory, Cost-Driven Switching From Originator Etanercept to Its Biosimilar SB4: Possible Fallout on Non-Medical Switching’ by Cantini and Benucci

Annals of the Rheumatic Diseases - United Kingdom
doi 10.1136/annrheumdis-2018-214788
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review

Rheumatology and Therapy
2019English

Observational Study of Inflammatory Arthritis Treatment by Etanercept Originator Switched to an Etanercept Biosimilar

Reumatologia
RheumatologyAllergyImmunology
2019English

Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden

Biologics in Therapy
2013English

Prm42 - Cost Model of Switching From Enbrel to Etanercept Biosimilars, for Non Medical Reasons, in Rheumatoid Arthritis Patients in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

A Real Concern or Just a Hype? – Evidence on Negative Clinical Consequences of Switching From Originator to Biosimilar Based on a Systematic Literature Review

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Does a Mandatory Non-Medical Switch From Originator to Biosimilar Infliximab Lead to Increased Use of Outpatient Healthcare Resources? A Register-Based Study in Patients With Inflammatory Arthritis

RMD Open
RheumatologyAllergyImmunology
2018English

SAT0161 Preliminary Real World Data on Switching Patterns Between Etanercept, Its Recently Marketed Biosimilar Counterpart and Its Competitor Adalimumab, Using Swedish Prescription Registry

2017English

Switching From Originator Biological Agents to Biosimilars: What Is the Evidence and What Are the Issues?

RMD Open
RheumatologyAllergyImmunology
2017English

Position on Non-Medical Switching for Diabetes Patients

Journal of Diabetes, Metabolic Disorders & Control
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy